3.62 USD
-0.12 (-3.21%)
3.6001 USD
-0.02 (-0.55%)
ChartMill assigns a Buy % Consensus number of 81% to ABCL. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 10.03. This target is 177.07% above the current price.
ABCL was analyzed by 14 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about ABCL.
In the previous month the buy percentage consensus was at a similar level.
ABCL was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-11-07 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2025-08-08 | Stifel | Maintains | Buy -> Buy |
| 2025-07-14 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-05-16 | Truist Securities | Maintains | Buy -> Buy |
| 2025-04-16 | Keybanc | Maintains | Overweight -> Overweight |
| 2025-03-03 | Benchmark | Reiterate | Hold -> Hold |
| 2025-02-28 | Stifel | Maintains | Buy -> Buy |
| 2025-01-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-11-05 | Benchmark | Reiterate | Hold |
| 2024-11-05 | Stifel | Reiterate | Buy -> Buy |
| 2024-08-20 | Benchmark | Downgrade | Buy -> Hold |
| 2024-07-11 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-05-08 | Keybanc | Maintains | Overweight -> Overweight |
| 2024-02-22 | Benchmark | Upgrade | Hold -> Buy |
| 2024-02-21 | Stifel | Maintains | Buy -> Buy |
| 2023-12-05 | Keybanc | Initiate | Overweight |
| 2023-08-31 | Benchmark | Maintains | Buy -> Buy |
| 2023-08-04 | Goldman Sachs | Maintains | Buy -> Buy |
| 2023-05-05 | Credit Suisse | Maintains | Outperform |
| 2023-02-28 | Cowen & Co. | Initiate | Outperform |
| 2023-02-22 | BMO Capital | Maintains | Outperform |
| 2023-02-22 | Credit Suisse | Reiterate | Outperform |
| 2023-01-06 | SVB Leerink | Maintains | Outperform |
| 2022-12-15 | Goldman Sachs | Initiate | Buy |
| 2022-11-16 | Truist Securities | Initiate | Buy |
| 2022-11-09 | SVB Leerink | Maintains | Outperform |
| 2022-08-10 | Credit Suisse | Maintains | Outperform |
| 2022-07-26 | Piper Sandler | Maintains | Overweight |
| 2022-05-11 | SVB Leerink | Maintains | Outperform |
| 2022-05-11 | Piper Sandler | Maintains | Overweight |
ABCELLERA BIOLOGICS INC / ABCL FAQ
What is the average price target for ABCELLERA BIOLOGICS INC (ABCL) stock?
14 analysts have analysed ABCL and the average price target is 10.03 USD. This implies a price increase of 177.07% is expected in the next year compared to the current price of 3.62.
What is the consensus rating for ABCELLERA BIOLOGICS INC (ABCL) stock?
The consensus rating for ABCELLERA BIOLOGICS INC (ABCL) is 81.4286 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover ABCELLERA BIOLOGICS INC (ABCL) stock?
The number of analysts covering ABCELLERA BIOLOGICS INC (ABCL) is 14.